Current approaches to the treatment of Parkinson’s disease

References

• AllainHCougnardJNeukirchHCSelegilene in de novo parkinsonian patients: the French selegiline multicenter trialActa Neurol Scand1991136738
   Web of Science ®Google Scholar
• AndersonVCBurchielKJHogarthPPallidal vs subthalamic nucleus deep brain stimulation in Parkinson diseaseArch Neurol2005625546015824252
   PubMed Web of Science ®Google Scholar
• AssalFSpahrLHadengueATolcapone and fulminant hepatitisLancet1998199589752821
   PubMed Web of Science ®Google Scholar
• BaroneIRektorIBaresMPramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized studyEur J Neurol20031039940612823492
   PubMed Web of Science ®Google Scholar
• BarontiFDavisTLBoldryRCDeprenyl effects on levodopa pharmacodynamics, mood and free radical scavengingNeurology19924254141549214
   PubMed Web of Science ®Google Scholar
• BejjaniBPGervaisDArnulfIAxial parkinsonian symptoms can be improved: the role of levodopa and bilateral subthalamic stimulationJ Neurol Neurosurg Psychiatry20006859560010766889
   PubMed Web of Science ®Google Scholar
• BhatiaKPMünchauABrownPBotulinum toxin is a useful treatment in excessive drooling of salivaJ Neurol Neurosurg Psychiatry19996769710577041
   PubMed Web of Science ®Google Scholar
• BlindauerKthe Parkinson Study GroupDelayed response to levodopa and response failures account for a large percentage of daily off time in advanced Parkinson’s disease patients with motor fluctuationsNeurology200360812
   Google Scholar
• BonnetAMInvolvement of non-dopaminergic pathways in Parkinson’s disease. Pathophysiology and therapeutic implicationsCNS Drugs20001335164
   Web of Science ®Google Scholar
• BorekLLChouKLFriedmanJHManagement of the behavioral aspects of Parkinson’s diseaseExpert Rev Neurother200777112517563253
   PubMedGoogle Scholar
• BreierASuttonVKFeldmanPDOlanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s diseaseBiol Psychiatry2002524384512242060
   PubMed Web of Science ®Google Scholar
• BrodskyMAGodboldJRothTOlanowCWSleepiness in Parkinson’s disease: A controlled studyMov Disord2003186687212784270
   PubMed Web of Science ®Google Scholar
• BrooksDJDopamine agonists: their role in the treatment of Parkinson’s diseaseJ Neurol Neurosurg Psychiatry2000686859010811688
   PubMed Web of Science ®Google Scholar
• BurchielKJAndersonVCFavreJComparison of pallidal and subthalamic nucleus deep brain stimulation for advances Parkinson’s disease: results of a randomized, blinded pilot studyNeurosurgery19994513758410598706
   PubMed Web of Science ®Google Scholar
• CeravoloRNutiAPicciniAParoxetine in Parkinson’s disease: Effects on motor and depressive symptomsNeurology2000551216811071504
   PubMed Web of Science ®Google Scholar
• ChaseTNOhJDStriatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonismTINS2000238691
   Web of Science ®Google Scholar
• CristinaSZangagliaRManciniFHigh-dose ropinirole in advanced Parkinson’s disease with severe dyskinesiasClin Neuropharmacol2003261465012782917
   PubMed Web of Science ®Google Scholar
• CummingsJLDepression and Parkinson’s disease: a reviewAm J Psychiatry1992149443541372794
   PubMed Web of Science ®Google Scholar
• DiamondAJankovicJThe effect of deep brain stimulation on quality of life in movement disordersJ Neurol Neurosurg Psychiatry20057611889316107348
   PubMed Web of Science ®Google Scholar
• DiamondAShahedJJankovicJThe effects of subthalamic nucleus deep brain stimulation on parkinsonian tremorJ Neurol Sci200726019920317561121
   PubMed Web of Science ®Google Scholar
• DoddMLKlosKJBowerJHPathological gambling caused by drugs used to treat Parkinson diseaseArch Neurol20056213778116009751
   PubMed Web of Science ®Google Scholar
• Driver-DunckleyESamantaJStacyMPathological gambling associated with dopamine agonist therapy in Parkinson’s diseaseNeurology200361422312913220
   PubMed Web of Science ®Google Scholar
• DujardinKSockeelPDevosDCharacteristics of apathy in Parkinson’s diseaseMov Disord2007227788417290451
   PubMed Web of Science ®Google Scholar
• EllisonRHDear health professional letter regarding appropriate use of Tasmar1998Nutley, NJRoche Laboratories Inc
   Google Scholar
• EmreMAarslandDAlbaneseARivastigmine for dementia associated with Parkinson’s diseaseN Engl J Med200435125091815590953
   PubMed Web of Science ®Google Scholar
• EtminanMGillSSamiiAComparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson’s disease: a meta-analysisDrug Saf2003264394412688834
   PubMed Web of Science ®Google Scholar
• EvansAHKatzenschlagerRPaviourDCPunding in Parkinson’s disease: its relation to the dopamine dysregulation syndromeMov Disord20041939740515077237
   PubMed Web of Science ®Google Scholar
• FabbriniFBarbantiPAuriliaCDonepezil in the treatment of hallucinations and delusions in Parkinson’s diseaseNeurol Sci20022341312111620
   PubMed Web of Science ®Google Scholar
• FactorSAFeustelPJFriedmanJHLongitudinal outcome of Parkinson’s disease patients with psychosisNeurology20036017566112796526
   PubMed Web of Science ®Google Scholar
• FahnSThe spectrum of levodopa-induced dyskinesiasAnn Neurol200047211
   PubMed Web of Science ®Google Scholar
• FénelonGMahieuxFHuonRZiéglerMHallucinations in Parkinson’s disease. Prevalence, phenomenology and risk factorsBrain20001237334510734005
   PubMed Web of Science ®Google Scholar
• FernandezHHTrieschmannMEFriedmanJHTreatment of psychosis in Parkinson’s disease; safety considerationsDrug Saf2003266435912814332
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationNew Warnings for Parkinson’s Drug Tasmar19981116Rockville, MDT9881
   Google Scholar
• FriedmanJHBermanRMGoetzCGOpen-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson’s diseaseMov Disord20062120788117013906
   PubMed Web of Science ®Google Scholar
• FriedmanJHChouKLSleep and fatigue in Parkinson’s diseaseParkinsonism Relat Disord2004102735
   PubMed Web of Science ®Google Scholar
• FriedmanJHFactorSAAtypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s diseaseMov Disord2000152011110752567
   PubMed Web of Science ®Google Scholar
• FriedmanJHPunding on levodopaBiol Psychiatry19943635017993965
   PubMed Web of Science ®Google Scholar
• FruchtSRogersJDGreenePDFalling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropiniroleNeurology19995219081010371546
   PubMed Web of Science ®Google Scholar
• GagnonJFPostumaRBMontplaisirJUpdate on pharmacology of REM sleep behavior disorderNeurology200667742716966533
   PubMed Web of Science ®Google Scholar
• GashDMZhangZGerhardtGNeuroprotective and neurorestorative properties of GDNFAnn Neurol1998441215
   Web of Science ®Google Scholar
• GiladiNMcDermottMPFahnSthe Parkinson Study GroupFreezing of gait in PD. Prospective assessment of the DATATOP cohortNeurology20015617122111425939
   PubMed Web of Science ®Google Scholar
• GillSSPatelNKHottonGRDirect brain infusion of glial cell line-derived neurotrophic factor in Parkinson diseaseNat Med200395899512669033
   PubMed Web of Science ®Google Scholar
• Gomez-EstebanJCZarranzJJVelascoFUse of ziprasidone in patients with psychosisClin Neuropharmacol200528111415965308
   PubMed Web of Science ®Google Scholar
• GrandasFHernandezBPRACTICOMT Study GroupLong-term effectiveness and quality of life improvement in entacapone-treated Parkinson’s disease patients: the effects of an early therapeutic interventionEur J Neurol200714282917355548
   PubMed Web of Science ®Google Scholar
• GrünblattEMandelSBerkuzkiTApomorphine protects against MPTP-induced neurotoxicity in miceMov Disord199914612810435498
   PubMed Web of Science ®Google Scholar
• HaberlerCAleschFMazalPRNo tissue damage by chronic deep brain stimulation in Parkinson’s diseaseAnn Neurol200048372610976644
   PubMed Web of Science ®Google Scholar
• HarizMIJohanssonFShamsgovaraPBilateral subthalamic nucleus stimulation in a parkinsonian patient with preoperative deficits in speech and cognition: Persistent improvement in mobility but increased dependency: A case studyMov Disord200015136910634253
   PubMed Web of Science ®Google Scholar
• HauserRAWahbaMNAndersonWMModafinil treatment of pramipexole-associated somnolenceMov Disord20001512697111104221
   PubMed Web of Science ®Google Scholar
• HauserRALevodopa/carbidopa/entacapone (Stalevo)Neurology2004626471
   PubMed Web of Science ®Google Scholar
• HeikkinenHVarheALylyVNew levodopa, carbidopa and entacapone combination tabletsEuropean J Neurology200310164
   Google Scholar
• HendersonJMPellMO’SullivanDJPostmortem analysis of bilateral subthalamic electrode implants in Parkinson’s diseaseMov Disord200217133711835450
   PubMed Web of Science ®Google Scholar
• HillMPBezardEBrotchieJMThe antiepileptic, levetiracetam (Keppra), modulates the process of priming for L-dopa-induced dyskinesia in MPTP-lesioned marmosetsEuropean J Neurology200310164
   Google Scholar
• JankovicJWattsRLMartinWTransdermal rotigotine: double-blind, placebo-controlled trial in Parkinson diseaseArch Neurol2007646768217502466
   PubMed Web of Science ®Google Scholar
• JankovicJNew and emerging therapies for Parkinson’s diseaseArch Neurol1999567859010404979
   PubMed Web of Science ®Google Scholar
• JankovicJParkinson’s disease therapy: Tailoring choices for early and late disease, young and old patientsClin Neuropharmacol2000232526111154092
   PubMed Web of Science ®Google Scholar
• JankovicJSurgery for Parkinson’s disease and other movement disorders: Benefits and limitations of ablation, stimulation, restoration, and radiationArch Neurol2001581970211735770
   PubMedGoogle Scholar
• JankovicJLevodopa strengths and weaknessesNeurology2002581932a
   PubMed Web of Science ®Google Scholar
• JankovicJJankovicJTolosaETherapeutic strategies in Parkinson’s diseaseParkinson’s Disease and Movement Disorders20024Philadelphia, PALippincott Williams and Wilkins116151b
   Google Scholar
• JankovicJMotor fluctuations and dyskinesias in Parkinson’s disease: Clinical manifestationsMov Disord200511116
   Web of Science ®Google Scholar
• JankovicJParkinson’s disease: clinical features and diagnosisJ Neurol Neurosurg Psychiatry2008a793687618344392
   PubMed Web of Science ®Google Scholar
• JankovicJAre adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson’s disease?Ann Neurol2008b63267918383071
   PubMed Web of Science ®Google Scholar
• JankovicJStacyMMedical management of levodopa-associate motor complications in patients with Parkinson’s diseaseCNS Drugs2007216779217630819
   PubMed Web of Science ®Google Scholar
• JouventRAbensourPBonnerAMAntiparkinsonian and antidepressant effects of high doses of bromocriptine. An independent comparisonJ Affect Disord1983514156222093
   PubMed Web of Science ®Google Scholar
• KompolitiKWangQEGoetzCGEffects of central dopaminergic stimulation by apomorphine on speech in Parkinson’s diseaseNeurology2000544586210668714
   PubMed Web of Science ®Google Scholar
• KorczynADBruntERLarsenJPA 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s diseaseNeurology1999533647010430427
   PubMed Web of Science ®Google Scholar
• KorczynADThalamasCAdlerCHDosing with ropinirole in a clinical settingActa Neurol Scand2002106200412225314
   PubMed Web of Science ®Google Scholar
• KordowerJHHerzogCDDassBDelivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeysAnn Neurol2006607061517192932
   PubMed Web of Science ®Google Scholar
• KrackPBatirAVan BlercomNFive-year follow up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s diseaseN Engl J Med200334919253414614167
   PubMed Web of Science ®Google Scholar
• KraussJKJankovicJGrossmanRGSurgery for Movement Disorders2001Philadelphia, PALippincott Williams and Wilkins1449
   Google Scholar
• KumarRLozanoAMSimeEComparative effects of unilateral and bilateral subthalamic nucleus deep brain stimulationNeurology199953561610449121
   PubMed Web of Science ®Google Scholar
• KurlanRDisabling repetitive behaviors in Parkinson’s diseaseMov Disord2004194336915077241
   PubMed Web of Science ®Google Scholar
• LangAEGillSPatelNKRandomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson’s diseaseAnn Neurol2006594596616429411
   PubMed Web of Science ®Google Scholar
• LeW-DJankovicJAre dopamine agonists neuroprotective in Parkinson’s disease?J Drugs and Aging20011838996
   PubMed Web of Science ®Google Scholar
• LeesAJKatzenschlagerRHeadJTen-year follow up of three different initial treatments in de-novo PD. A randomized trialNeurology20015716879411706112
   PubMed Web of Science ®Google Scholar
• LeesAJRatziuVTolosaESafety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson’s diseaseJ Neurol Neurosurg Psychiatry200778944817098835
   PubMed Web of Science ®Google Scholar
• LeWittPALyonsKEPahwaRSP 650 Study GroupAdvanced Parkinson disease treated with rotigotine transdermal system: PREFER StudyNeurology2007681262717438216
   PubMed Web of Science ®Google Scholar
• LinazasoroGVan BlercomNLasaAUnilateral subthalamic deep brain stimulation in advanced Parkinson’s diseaseMov Disord200318713612784280
   PubMed Web of Science ®Google Scholar
• LuckGCBrownRGApathy in Parkinson’s diseaseJ Neurol Neurosurg Psychiatry2002736364212438462
   PubMed Web of Science ®Google Scholar
• LuckingCBDurrABonifatiVAssociation between early onset Parkinson’s disease and mutations in the parkin geneNew Engl J Med200034215606710824074
   PubMed Web of Science ®Google Scholar
• LugingerEWenningGKBöschSBeneficial effects of amantadine on dopa-induced dyskinesias in Parkinson’s diseaseMov Disord200015873811009193
   PubMed Web of Science ®Google Scholar
• ManciniFTassorelliCMartignoniELong term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson’s diseaseClin Neuropharmacol20042733715090935
   PubMed Web of Science ®Google Scholar
• MansonAJTurnerKLeesAJApomorphine monotherapy in the treatment of refractory motor complications of Parkinson’s disease: Long-term follow up study of 64 patientsMov Disord20021712354112465062
   PubMed Web of Science ®Google Scholar
• MarksWLVerhagen MetmanLStarrPNeurturin gene transfer for Parkinson’s disease: motor outcomes from the initial CERE-120 clinical trialMov Disord200621608
   Web of Science ®Google Scholar
• MarrasCLangAEMeasuring motor complications in clinical trials for early Parkinson’s diseaseJ Neurol Neurosurg Psychiatry200374143612531932
   PubMed Web of Science ®Google Scholar
• MerimsDBalasMPeretzCRater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson’s disease psychosisClin Neuropharmacol200629331717095896
   PubMed Web of Science ®Google Scholar
• MiyasakiJMAl HassanKLangAEPunding prevalence in Parkinson’s diseaseMov Disord20072211798117230464
   PubMed Web of Science ®Google Scholar
• MiyasakiJMShannonKVoonVPractice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson’s disease (an evidence-based review). Report of the subcommittee of the American Academy of NeurologyNeurology200666996100216606910
   PubMed Web of Science ®Google Scholar
• NakaoNNakaiTNakaiKAblation of the subthalamic nucleus supports the survival of nigral dopaminergic neurons after nigrostriatal lesions induced by the mitochondrial toxin 3-nitropropionic acidAnn Neurol1999456405110319887
   PubMed Web of Science ®Google Scholar
• NuttJGBurchielKJComellaCLRandomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PDNeurology200360697312525720
   PubMed Web of Science ®Google Scholar
• NuttJGCarterJHApomorphine can sustain the long-duration response to L-DOPA in fluctuating PDNeurology2000542475010636162
   PubMed Web of Science ®Google Scholar
• NuttJGContinuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?Mov Disord2007221916958130
   PubMed Web of Science ®Google Scholar
• ObesoJARodriguez-OrozMCRodriguezMPathophysiology of the basal ganglia in Parkinson’s diseaseTINS200023819
   PubMed Web of Science ®Google Scholar
• OlanowCWTasmar Advisory PanelTolcapone and hepatotoxic effectsArch Neurol2000572636710681087
   PubMed Web of Science ®Google Scholar
• OndoWHunterCAlmaguerMEfficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson’s diseaseClin Neuropharmacol19992214a10047926
   PubMed Web of Science ®Google Scholar
• OndoWHunterCAlmaguerMSublingual apomorphine in patients with fluctuating Parkinson’s diseaseMov Disord1999146648b10435505
   PubMed Web of Science ®Google Scholar
• OndoWJankovicJSchwartzKUnilateral thalamic deep brain stimulation for refractory essential tremor and Parkinson’s disease tremorNeurology199851106399781530
   PubMed Web of Science ®Google Scholar
• OndoWGFayleRAtassiFModafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trialJ Neurol Neurosurg Psychiatry20057616369b16291885
   PubMed Web of Science ®Google Scholar
• OndoWGLevyJKVuonKVOlanzapine treatment for dopaminergic-induced hallucinationsMov Disord2002171031512360554
   PubMed Web of Science ®Google Scholar
• OndoWGTintnerRDat VoungKDouble blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s diseaseMov Disord20052095863a15800937
   PubMed Web of Science ®Google Scholar
• OndoWGVuongKVKhanHDaytime sleepiness and other sleep disorders in Parkinson’s diseaseNeurology2001571392611673578
   PubMed Web of Science ®Google Scholar
• PactVGiduzTMirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesiasNeurology199953115410496290
   PubMed Web of Science ®Google Scholar
• PalPKCalneDBCalneSBotulinum-A toxin in the treatment of sialorrhea in patients with Parkinson’s diseaseParkinsonism Relat Disord1999582
   Web of Science ®Google Scholar
• Parkinson Study GroupDopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progressionJAMA200228716536111926889
   PubMed Web of Science ®Google Scholar
• Parkinson Study GroupA controlled trial of rotigotine monotherapy in early Parkinson’s diseaseArch Neurol2003601721814676046
   PubMedGoogle Scholar
• Parkinson Study GroupA randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO studyArch Neurol200562241815710852
   PubMed Web of Science ®Google Scholar
• Pereira da Silva-JuniorFBraga-NetoPSueli MonteFAmantadine reduces the duration of levodopa-induced dyskinesia: A randomized, double-blind, placebo-controlled studyParkinsonism Relat Disord2005114495216154788
   PubMed Web of Science ®Google Scholar
• PietzKHagellPOdinPSubcutaneous apomorphine in late stage Parkinson’s disease: a long term follow upJ Neurol Neurosurg Psychiatry199865709169810943
   PubMed Web of Science ®Google Scholar
• PillonBArdouinCDamierPNeuropsychological changes between “off” and “on” STN or GPi stimulation in Parkinson’s diseaseNeurology200055411810932277
   PubMed Web of Science ®Google Scholar
• PoeweWLeussiFClinical studies with transdermal rotigotine in early Parkinson’s diseaseNeurology20056511416009878
   PubMed Web of Science ®Google Scholar
• PoeweWWenningGKApomorphine: An underutilized therapy for Parkinson’s diseaseMov Disord2000157899411009181
   PubMed Web of Science ®Google Scholar
• RabeyJMProkhorovTMiniovitzAEffect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ durationMov Disord200722313817034006
   PubMed Web of Science ®Google Scholar
• RajputAHFentonMEBirdiSClinical pathological study of levodopa complicationsMov Disord2002172899611921114
   PubMed Web of Science ®Google Scholar
• RascolOBrooksDJKorczynADA five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study GroupN Engl J Med20001814849110816186
   PubMed Web of Science ®Google Scholar
• RascolOBrooksDJMelamedELARGO study groupRasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trialLancet20053659475415766996
   PubMed Web of Science ®Google Scholar
• RavinaBCamicioliRComoPGThe impact of depressive symptoms in early Parkinson’s diseaseNeurology200769342717581943
   PubMed Web of Science ®Google Scholar
• ReadingPJLuceAKMcKeithIJRivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trialMov Disord20011611719511748755
   PubMed Web of Science ®Google Scholar
• ReisbergBDoodyRStofflerAMemantine Study GroupMemantine in moderate-to-severe Alzheimer’s diseaseN Engl J Med200334813334112672860
   PubMed Web of Science ®Google Scholar
• RektorovaIRektorIBaresMPramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre perspective randomized studyEur J Neurol20031039940612823492
   PubMed Web of Science ®Google Scholar
• ReynerLAHorneJAFalling asleep whilst driving: are drivers aware of prior sleepiness?Int J Legal Med199811112039587793
   PubMed Web of Science ®Google Scholar
• RichSSFriedmanJHOttBRRisperidone versus clozapine in the treatment of psychosis in six patients with Parkinson’s disease and other akinetic-rigid syndromesJ Clin Psychiatry19955655698530331
   PubMed Web of Science ®Google Scholar
• RichardIHAnxiety disorders in Parkinson’s diseaseAdv Neurol200596425516383211
   PubMedGoogle Scholar
• Rodriguez-OrozMCObesoJALangAEBilateral deep brain stimulation in Parkinson’s disease: a multicentre study with 4 years follow upBrain20051282240915975946
   PubMed Web of Science ®Google Scholar
• RothBLDrugs and valvular heart diseaseN Engl J Med20073566917202450
   PubMed Web of Science ®Google Scholar
• RuottinenHMRinneUKCOMT inhibition in the treatment of Parkinson’s diseaseJ Neurol19982452534
   Web of Science ®Google Scholar
• Saint-CyrJATrepanierLLKumarRNeuropsychologic consequences of chronic bilateral stimulation of the STN in Parkinson’s diseaseBrain2000123209110811004126
   PubMed Web of Science ®Google Scholar
• SchapiraAHOlanowCWNeuroprotection in Parkinson’s Disease: mysteries, myths and misconceptionsJAMA20042913586414734599
   PubMed Web of Science ®Google Scholar
• SchragASchottJMEpidemiological, clinical and genetic characteristics of early-onset parkinsonismLancet Neurol200653556316545752
   PubMed Web of Science ®Google Scholar
• SchragAEntacapone in the treatment of Parkinson’s diseaseLancet Neurol200543667015907741
   PubMed Web of Science ®Google Scholar
• SchragASQuinnNDyskinesias and motor fluctuations in Parkinson’s disease. A community-based studyBrain2000123229730511050029
   PubMed Web of Science ®Google Scholar
• SchuurmanPRBoschABossuytPMMA comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremorN Engl J Med2000342461810675426
   PubMed Web of Science ®Google Scholar
• ShibaMBowerJHMaragnoreDMAnxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control studyMov Disord2000156697710928577
   PubMed Web of Science ®Google Scholar
• ShoulsonIOakesDFahnSImpact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: A randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trialAnn Neurol2002516041212112107
   PubMed Web of Science ®Google Scholar
• ShultsCWOakesDKieburtzKEffects of coenzyme q10 in early Parkinson disease: evidence of slowing of the functional declineArch Neurol20025915415012374491
   PubMed Web of Science ®Google Scholar
• SimpkinsNJankovicJNeuroprotection in Parkinson’s diseaseArch Int Med20031631650412885679
   PubMedGoogle Scholar
• StarksteinSEMaybergHSPreziosiTJReliability, validity, and clinical correlates of apathy in Parkinson’s diseaseJ Neuropsychiatry Clin Neurosci1992413491627973
   PubMed Web of Science ®Google Scholar
• SteinMBHeuserIJJuncosJLAnxiety disorders in patients with Parkinson’s diseaseAm J Psychiatry1990147217202301664
   PubMed Web of Science ®Google Scholar
• SternMBMarekKLFriedmanJDouble-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson’s disease patientsMov Disord2004199162315300656
   PubMed Web of Science ®Google Scholar
• SternMBDopamine agonists modify the course of Parkinson diseaseArch Neurol20046119697115596624
   PubMedGoogle Scholar
• StocchiFVaccaLBerardelliADual dopamine agonist treatment in Parkinson’s diseaseJ Neurol2003250822612883924
   PubMed Web of Science ®Google Scholar
• StocchiFVaccaLRuggieriSIntermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic studyArch Neurol2005629051015956161
   PubMed Web of Science ®Google Scholar
• StoverNPBakayRASubramanianTIntrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson diseaseArch Neurol20056218337a16344341
   PubMed Web of Science ®Google Scholar
• StoverNPOkunMSEvattMLStimulation of the subthalamic nucleus in a patient with Parkinson disease and essential tremorArch Neurol2005621413b15642861
   PubMedGoogle Scholar
• TakeshitaSKurisuKTropLEffect of subthalamic stimulation on mood state in Parkinson’s disease: evaluation of previous facts and problemsNeurosurg Rev2005281798615827764
   PubMed Web of Science ®Google Scholar
• TanEKOndoWClinical characteristics of pramipexole-induced peripheral edemaArch Neurol2000577293210815140
   PubMed Web of Science ®Google Scholar
• TandbergELarsenJPAarslandDThe occurrence of depression in Parkinson’s disease. A community-based studyArch Neurol19965417598639068
   PubMedGoogle Scholar
• TintnerRManianPGauthierPPleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson diseaseArch Neurol2005621290516087771
   PubMedGoogle Scholar
• VazquezAJimenez-JimenezFJGarcia-RuizP“Panic attacks” in Parkinson’s disease: a long-term complication of levodopa therapyActa Neurol Scand1993871488424307
   PubMed Web of Science ®Google Scholar
• Verhagen MetmanLDottoPDLePooleKAmantadine for levodopa-induced dyskinesias. A 1-year follow up studyArch Neurol1999561383610555659
   PubMedGoogle Scholar
• Verhagen MetmanLKonitsiotisSChaseTNPathophysiology of motor response complications in Parkinson’s disease: Hypotheses on the why, where, and whatMov Disord2000153810634235
   PubMed Web of Science ®Google Scholar
• VoonVThomsenTMiyasakiJMFactors associated with dopaminergic drug-related pathological gambling in Parkinson diseaseArch Neurol200764212617296836
   PubMed Web of Science ®Google Scholar
• VoonVRepetition, repetition and repletion: compulsion and punding behaviors in Parkinson’s diseaseMov Disord2004193677015077233
   PubMed Web of Science ®Google Scholar
• WattsRLJankovicJWatersCRandomized, blind, controlled trial of transdermal rotigotine in early Parkinson diseaseNeurology200768272617202432
   PubMed Web of Science ®Google Scholar
• WattsRLRaiserCDStoverNPStereotaxic intrastriatal implantation of human retinal pigment epithelial (hRPE) cells attached to gelatin microcarriers: a potential new cell therapy for Parkinson’s diseaseJ Neural Transm Suppl2003652152712946059
   PubMedGoogle Scholar
• WeinerWJFactorSAJankovicJThe long-term safety and efficacy of pramipexole in advanced Parkinson’s diseaseParkinsonism Relat Disord200171152011248592
   PubMed Web of Science ®Google Scholar
• WeinerWJInitial treatment of Parkinson disease: levodopa or dopamine agonistsArch Neurol2004611966915596623
   PubMedGoogle Scholar
• WeintraubDSternWBIntervening in the neuropsychiatric features of Parkinson’s diseaseExpert Rev Neurother2007769971017563252
   PubMedGoogle Scholar
• WhoneALWattsRLStoesslAJSlower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET studyAnn Neurol2003549310112838524
   PubMed Web of Science ®Google Scholar
• WilkinsonDGPassmoreAPBullockRA multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer’s diseaseInt J Clin Pract200256441612166542
   PubMed Web of Science ®Google Scholar
• Williams-GrayCHFoltynieTLewisSJGCognitive deficits and psychosis in Parkinson’s disease: A review of Pathophysiology and therapeutic optionsCNS Drugs20062047750516734499
   PubMed Web of Science ®Google Scholar
• WolozinBWangSWLiNCSimvastatin is associated with a reduced incidence of dementia and Parkinson’s diseaseBMC Med200719520
   Google Scholar
• ZanettiniRAntoniniAGattoGValvular heart disease and the use of dopamine agonists for Parkinson’s diseaseNew Eng J Med2007356394617202454
   PubMed Web of Science ®Google Scholar
• ZesiewiczTAGoldMChariGThe occurrence of depression in Parkinson’s diseaseArch Neurol1999531759
   Google Scholar
• ZhangSMHernanMAChenHIntakes of vitamins E and C, carotenoids, vitamin supplements, and PD riskNeurology2002591161912391343
   PubMed Web of Science ®Google Scholar
• ZouLJankovicJRoweDBNeuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicityLife Sci19996412758510227583
   PubMed Web of Science ®Google Scholar